In their last earnings report on Mar 31, 2025, Becton Dickinson & Co. (BDX) reported $2.76B of revenue from Medical, $1.26B of revenue from Interventional, $1.25B of revenue from Life Sciences and $0 of revenue from Other.
BDX
reported a total revenue of $5.27B
across all segments
on Mar 31, 2025,
up from $5.17B the previous quarter on Dec 31, 2024
and down from $5.05B one year prior on Mar 31, 2024.
This is a change of 1.97% from the previous quarter and
4.48% from one year prior.